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Brown adipose tissue is the key depot for glucose
clearance in microbiota depleted mice
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Gut microbiota deficient mice demonstrate accelerated glucose clearance. However, which
tissues are responsible for the upregulated glucose uptake remains unresolved, with different
studies suggesting that browning of white adipose tissue, or modulated hepatic gluconeo-
genesis, may be related to enhanced glucose clearance when the gut microbiota is absent.
Here, we investigate glucose uptake in 22 different tissues in 3 different mouse models. We
find that gut microbiota depletion via treatment with antibiotic cocktails (ABX) promotes
glucose uptake in brown adipose tissue (BAT) and cecum. Nevertheless, the adaptive ther-
mogenesis and the expression of uncoupling protein 1 (UCP1) are dispensable for the
increased glucose uptake and clearance. Deletion of Ucp1 expressing cells blunts the
improvement of glucose clearance in ABX-treated mice. Our results indicate that BAT and
cecum, but not white adipose tissue (WAT) or liver, contribute to the glucose uptake in the
gut microbiota depleted mouse model and this response is dissociated from adaptive
thermogenesis.
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Brown adipose tissue (BAT) primarily evolved as a source ofnonshivering thermogenesis that generates endogenousheat, which sustains body temperature in the face of cold
exposure1. In the past decades, BAT thermogenesis guided by
uncoupling protein 1 (UCP1) has been well-characterized and
involves allowing protons to bypass complex 5 of the oxidative
phosphorylation pathway, and instead move directly from the
mitochondrial intermembrane space to the matrix releasing their
stored chemiosmotic potential as heat2. UCP1 plays a crucial role
in preventing fatal hypothermia during acute cold exposure in
rodents3. However, about 15% of Ucp1-null mice can survive
mild cold challenge, suggesting UCP1 is not essential for long-
term survival in the cold4,5. This led to speculation about the
existence of other heat generating mechanisms in Ucp1-null mice,
including extended shivering in skeletal muscle6 or nonshivering
UCP1-independent thermogenic mechanisms. Such mechanisms
include creatine and SERCA futile pathways7–11. The discovery
that adult humans possess activated BAT was made using F18-
fluorodeoxyglucose positron emission tomography12–14. This
observation also revealed the importance of BAT in facilitating
whole-body glucose homeostasis. Acute cold stimulation15 or
BAT transplantation16,17 can improve glucose tolerance and
insulin sensitivity and these effects are often attributed to acti-
vated BAT thermogenesis. However, it is not clear whether the
capacity of glucose uptake in BAT can proportionally reflect the
nonshivering thermogenesis measured by indirect calorimetry or
doubly labeled water (DLW)18.
The earliest observation suggesting the gut microbiota also
participates in fat storage and blood glucose regulation was that
germ-free (GF) mice have better glucose homeostasis compared
to conventional mice19. Later, accumulating studies also
demonstrated that depletion of the gut microbiota improves
glucose tolerance in obese hosts20,21. However, the consequences
of microbiota depletion for glucose absorption in different host
tissues are currently unknown. It is also unresolved which tissue
(s) are mostly responsible for the improved glucose uptake in
microbiota-depleted animals. Studies have suggested that
browning of white adipose tissue (WAT)22, hepatic
gluconeogenesis23 or altered cecum enterocyte metabolism20 may
contribute to blood glucose regulation when the gut microbiota is
absent. These previous studies reported both antibiotic-treated
and germ-free mice have a browning phenotype in their WAT at
both room temperature (22 °C) and thermoneutrality (30 °C), and
they concluded that the promotion of browning WAT leads to
improved glucose tolerance in the microbiota-depleted mice22.
Although some evidence suggested that browning of WAT
increased capacity to combust glucose and fatty acids24, among
the adipose tissues BAT dominates glucose utilization due to the
much higher abundance of mitochondria compared with any of
the WAT depots25. Additionally, our and others’ studies have
revisited the impact of microbiota depletion on BAT and WAT
thermogenesis and found that the process of UCP1-dependent
adaptive thermogenesis is impaired in the absence of the gut
microbiota26,27. A recent study, however, suggested that the gut
microbiota effect is an artefact of the way energy expenditure data
were analyzed, and that there is no impact on energy expenditure
in the cold, once the effect of microbiota depletion on the size of
the cecum, and hence elevated contribution of the gut contents to
total body mass is taken into account23. Nevertheless, this latter
study does not distinguish the influence of gut microbiota on
UCP1-dependent and UCP1-independent thermogenesis because
cold prehabituation can also boost UCP1-independent thermo-
genesis. They further claimed that gut microbiota-depleted mice
do not differ in their performance on the glucose tolerance test or
insulin tolerance test, but only have blunted hepatic gluconeo-
genesis and lower basal blood glucose. However, these
conclusions are inconsistent with many earlier studies19,20,28,29.
These previous studies have focused on WAT or liver as the site
for improved glucose homeostasis, but the contribution of BAT in
regulating blood glucose after ABX treatment has been largely
overlooked. Hence, further investigation is needed to establish
whether the improved glucose metabolism in microbiota-
deficient mice is real, and if so, if it stems from browning of
WAT, hepatic gluconeogenesis or the activation of other tissues
such as BAT.
In this work, the main aims are: (1) to re-evaluate the effects of
gut microbiota depletion on glucose clearance in mice; (2) to
investigate whether the amelioration of glucose clearance was a
secondary effect of activated thermogenesis in microbiota-
deficient mice; (3) to define the contribution of BAT in mod-
ulating glucose uptake in microbiota-deficient mice. We confirm
that antibiotic-mediated microbiota depletion improves glucose
clearance in mice. We also find that microbiota depletion boosts
glucose uptake in BAT and cecum, but neither WAT nor liver,
and this response is dissociated from adaptive thermogenesis.
Importantly, we show that selective deletion of brown adipocytes
mitigates the improvement of glucose clearance in ABX mice.
Results
Gut microbiota depletion promotes glucose uptake in brown
adipose tissue. To test the effect of gut microbiota depletion on
glucose metabolism in mice, we used the antibiotic cocktail
protocol (ABX) used previously, for 3–4 weeks26, which origi-
nated from Abt et al.30. Compared to the specific-pathogen-free
mice fed with low fat diet (LFD) and housed under conventional
conditions (Control), ABX-treated mice exhibited an improve-
ment in glucose clearance in an intraperitoneal glucose tolerance
test (ipGTT) at room temperature (22 °C) and cold exposure at
4 °C for 48 h (two-way ANOVA, F3, 36= 90.55, P < 0.001)
(Fig. 1a). Of note, although cold stimulation accelerated glucose
clearance in the Control group, it did not further augment glucose
clearance in ABX group. Glucose is normally oxidized by mito-
chondria into water and CO2 through the reactions of the citric
acid cycle and oxidative phosphorylation after transport from the
circulation into cells. Excess nonmetabolized glucose can also be
converted into glycogen or fatty acids when energy demand is
attenuated31. To determine the state of the glucose mobilization,
we conducted a CO2 breath analysis test using 13C-labeled glu-
cose (Fig. 1b). Similar to our previous [U13C] butyrate
experiment26, we intraperitoneally injected a solution containing
a mixture of [U13C] and 12C glucose to fasted Control and ABX
mice. Compared to 22 °C, cold stimulation (4 °C) boosted 13CO2
production suggesting cold stimulation elevated glucose oxida-
tion. ABX mice had about 1.2-fold higher peak 13CO2 output
than Control mice at 4 °C (two-way ANOVA, F24, 432= 9.243, P
< 0.001) and no difference was found at 22 °C (Fig. 1c).
To determine the tissues primarily responsible for glucose uptake
following depletion of the microbiota, we repeated the same isotope
experiment in a second cohort (Fig. 1b). We measured 13C content
in 22 tissues 25–30min after injection (at the peak point of 13CO2
output). The overall 13C glucose uptake was summarized in Fig. 1d.
We found cold stimulation enhanced glucose distribution into BAT.
At 4 °C, ABX mice had significantly higher 13C levels in BAT (two-
way ANOVA, F3, 107= 106.8, P < 0.001), heart (two-way ANOVA,
F3, 106= 6.589, P= 0.017), and liver (two-way ANOVA, F3, 106=
6.589, P= 0.005) compared to Control mice (Fig. 1e and
Supplementary Fig. 1a). At 22 °C, ABX mice had higher 13C levels
in stomach and colon (two-way ANOVA, F3, 101= 13.47, P= 0.04)
(Supplementary Fig. 1b). There was no difference of glucose uptake
in different skeletal muscle depots between Control and ABX mice
(two-way ANOVA, F3, 104= 0.0544, P= 0.816) (Fig. 1f). Upon cold
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stimulation, Control mice decreased glucose uptake into skeletal
muscles whereas ABX mice did not (Fig. 1f). There was no
difference in 13C enrichment between Control and ABX mice in
inguinal, epididymal, mesenteric or retroperitoneal WAT at both
22 °C and 4 °C (two-way ANOVA, F3, 80= 1.426, P= 0.239)
(Fig. 1e and Supplementary Fig. 1c). The 13C levels in the remaining
tissues was unchanged after ABX treatment (Supplementary
Fig. 1a–c). Consistent with our previous study26, ABX mice had
lower white fat mass from different anatomic sites (Supplementary
Fig. 1d–g).
The 13C glucose uptake experiment reflected the net levels of
glucose content in different tissues 30min after glucose injection.
That is the difference between uptake and utilization. To further
confirm the redistribution of glucose in the microbiota-depleted mice
focusing only on uptake, we injected a mixture of [U13C] 2-Deoxy-
D-glucose (2DG) and 12C glucose solution at the same ratio as in the
13C glucose experiment to fasted Control and ABX mice (Fig. 1b).
Although the glucose transporters can import 2DG into cells, the
modification of 2-hydroxyl group in 2DG prevents its degradation32.
Hence, using isotope labeled 2DG allowed us to measure the
cumulative glucose uptake from the time of injection to the peak
point, independent of utilization. The overall 13C 2DG uptake was
summarized in Fig. 1g. At 4 °C, similar to the 13C glucose
experiment, ABX mice had significant higher 13C-labeled 2DG in
BAT (two-way ANOVA, F3, 29= 29.00, P < 0.001) and heart (two-
way ANOVA, F3, 30= 5.304, P= 0.017) (Fig. 1h and Supplementary
Fig. 1h). Cold stimulation decreased 13C levels in skeletal muscles in
Control mice (two-way ANOVA, F1, 59= 24.92, P < 0.001) but not in
ABX mice (two-way ANOVA, F1, 59= 3.832, P= 0.055) (Fig. 1i). At
22 °C, ABX mice had higher 13C-labeled 2DG in BAT (two-way
ANOVA, F3, 29= 29.00, P= 0.013) and cecum (two-way ANOVA,
F3, 30= 63.84, P < 0.001) (Fig. 1h and Supplementary Fig. 1i). We did
not observe any difference in cumulative 13C levels in the rest of the
tissues including all WAT depots and liver after ABX treatment
Fig. 1 Gut microbiota depletion promotes glucose uptake in brown adipose tissue. a Intraperitoneal glucose tolerance test (ipGTT) and total glucose area
under the curves (AUC) (n= 10 per group). Control: 22 °C group (black square), ABX:22 °C group (red circle), Control: 4 °C group (black empty square)
and ABX:4 °C group (red empty circle) (GTT-Ctrl :22 °C vs ABX:22 °C, P < 0.001 at T= 0, 15, 30, 60, 120; GTT-Ctrl :4 °C vs ABX:4 °C, P= 0.001 at T= 0,
P < 0.001 at T= 15, 30, 60, 120; GTT-Ctrl :22 °C vs Ctrl:4 °C, P < 0.001 at T= 15, 30, P= 0.007 at T= 60. AUC-Ctrl :22 °C vs ABX:22 °C, P < 0.001; AUC-
Ctrl :4 °C vs ABX:4 °C, P= 0.001; AUC-Ctrl :22 °C vs Ctrl:4 °C, P < 0.001). b Experimental scheme. 4 weeks ABX-treated mice were randomly housed at
22 °C or 48 h acute cold exposure. Then overnight fasted mice were intraperitoneal injected with [U-13C] labelled glucose or 2DG solutions. c Glucose
metabolized CO2 was determined by 13C enrichment in breath samples at 10 min interval after intraperitoneal injection of [U-13C] labelled glucose at 22 °C
or 4 °C (n= 8 per group) (T= 30min, P < 0.001). d Hierarchical clustering of [U-13C] glucose enrichment (per mil) from 22 tissues based on 13C levels
(Ctrl:22 °C, n= 8; Ctrl:4 °C, n= 8; ABX:22 °C, n= 8; ABX:4 °C, n= 7). e, f 13C enrichment in fat depots (e) (BAT: all shown P < 0.001) and skeletal muscle
(f) after injection of [U-13C] labelled glucose (Ctrl:22 °C, n= 8; Ctrl:4 °C, n= 8; ABX:22 °C, n= 8; ABX:4 °C, n= 7). g Hierarchical clustering of [U-13C]
2DG enrichment (per mil) from 22 tissues (Ctrl:22 °C, n= 8; Ctrl:4 °C, n= 9; ABX:22 °C, n= 9; ABX:4 °C, n= 8). h, i 13C enrichment in fat depots (h)
(BAT: Ctrl :22 °C vs ABX:22 °C, P= 0.013; BAT: Ctrl :4 °C vs ABX:4 °C, P < 0.001; BAT: Ctrl :22 °C vs Ctrl:4 °C, P < 0.001; BAT: ABX:22 °C vs ABX:4 °C, P
< 0.001;) and skeletal muscle (i) after injection of [U-13C] labelled 2DG (Ctrl:22 °C, n= 8; Ctrl:4 °C, n= 9; ABX:22 °C, n= 9; ABX:4 °C, n= 8). j 13C
glucose turnover rate in four groups using an exponential uptake-elimination model. All statistical analyses were performed by two-way ANOVA with
Bonferroni’s multiple comparisons. All results are given as mean ± SEM. Differences with P < 0.05 were considered to be significant. P < 0.05 (* or $), P <
0.01 (** or $$), and P < 0.001 (*** or $$$). SV seminal vesicle, iWAT inguinal WAT, epWAT epididymal WAT, mWAT mesenteric WAT, rpWAT
retroperitoneal WAT. See also Supplementary Fig. 1.
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(Supplementary Fig. 1h and Supplementary Fig. 1j). Different to the
13C glucose experiment, the 13C 2DG level in the liver did not show a
difference. This could be because 2DG only reflects glucose uptake
while the glucose tracer reflected glucose uptake and utilization.
Notably, the capacity of basal glucose utilization in all WAT depots
was trivial compared to other tissues and ABX treatment failed to
enhance the glucose turnover, whereas ABX mice had higher glucose
turnover in BAT and cecum (Fig. 1j).
Overall, we found that ABX treatment accelerated glucose
clearance and our two isotope tracer experiments showed that
ABX treatment only increased glucose uptake and utilization in
BAT and tissues of the alimentary tract. In ABX mice, cold
exposure further stimulated glucose uptake in BAT and heart. We
did not detect differences in 13C levels in all WAT depots
(inguinal, epididymal, mesenteric, or retroperitoneal WAT) and
liver. These data indicated that BAT, heart, and the alimentary
tract, rather than WAT depots or liver, are the most important
sites for enhanced glucose disposal when gut microbiota was
absent.
Gut microbiota is not required for UCP1-independent ther-
mogenesis. ABX treatment leads to a reduction of UCP1
expression and impairment of UCP1-dependent adaptive ther-
mogenesis in low fat diet (LFD) fed wild-type mice26. Since UCP1
is dispensable for long-term thermoregulation but essential for
survival in the acute cold challenge, it is important to distinguish
the effect of gut microbiota depletion on UCP1-dependent and
UCP1-independent thermogenesis. To this end, we treated LFD-
fed Ucp1-KO mice and their wild-type siblings with the ABX
cocktail for 4–5 weeks at room temperature (Fig. 2a and Sup-
plementary Fig. 2a). As in previous studies3,33,34, we found that
Ucp1-KO mice had similar body weight compared to sibling
controls at 22 °C. Additionally, we also found 4 weeks of ABX
treatment did not significantly lower their body weight (Supple-
mentary Fig. 2b). Magnetic resonance spectroscopy (MRS) ana-
lyses revealed that ABX treatment lowered total body fat in wild-
type mice (two-way ANOVA, F3, 64= 2.571, P < 0.001) but not in
Ucp1-KO mice (two-way ANOVA, F3, 64= 2.571, P= 0.165)
(Fig. 2b). We assessed the glucose clearance in ipGTT at the 3rd
week of ABX treatment. Although control treated Ucp1-KO mice
had similar body weight and total body fat to the control treated
wild-type mice, we found that control treated Ucp1-KO mice had
impaired glucose clearance compared with wild-type mice (one-
way ANOVA, F3, 33= 4.261, P= 0.003). After ABX treatment,
both Ucp1-KO and wild-type mice had significantly improved
glucose clearance (one-way ANOVA, F3, 33= 4.261, P < 0.001)
(Fig. 2c, d).
Although we previously reported that the gut microbiota is
required for UCP1-dependent thermogenesis of BAT in wild-type
mice26, a recent study has challenged this notion and reported the
gut microbiota is dispensable to β3-adrenoceptor activation in the
commensal-depleted (CD) mice23. Despite the difference in the
experimental animals, 1 h stimulation of CL-316243 is insufficient
to evaluate the activation of thermogenesis. To address these
conflicting results, we repeated our experiment at 4.5 weeks of
ABX treatment with a shorter data collection interval (6 min per
data point) than our previous measurement, which allows us to
observe more detailed information using indirect calorimetry
(TSE PhenoMaster). As the response to CL-316243 stimulation,
both Control and ABX-treated wild-type mice immediately
elevated their oxygen consumption. The oxygen consumption
reached a plateau after about 6 h and further increased as the
mice entered the dark phase. The oxygen consumption did not
differ significantly between Control and ABX-treated wild-type
mice over the first hours (ANCOVA, F1, 11= 0.02, P= 0.8901),
which was consistent with the result in Krisko et al., but ABX-
treated wild-type mice failed to maintain the high oxygen
consumption rate and significantly dropped by about 10% after
6 h of CL-316243 stimulation (ANCOVA, F1, 11= 3.36, P=
0.033) (Fig. 2e, f). Since UCP1 is essential for adaptive adrenergic
nonshivering thermogenesis35,36, both Control and ABX-treated
Ucp1-KO mice did not respond to CL-316243 stimulation. The
activation of β3-adrenoceptor leads to lipolysis, which was
evident in respiratory exchange ratio (RER). Following CL-
316243 injection, RER declined from 0.9 to less than 0.8 in the
four groups of mice indicating that fat was being increasingly
used for energy combustion. A persistent low RER in Control
treated wild-type mice was observed where the RER in other three
groups regained their basal levels after dark phase (two-way
ANOVA, F3, 27= 21.00, P < 0.001) (Fig. 2g, h). We did not
observe any difference in physical activity among four groups
during the light phase (two-way ANOVA, F3, 27= 3.396, P >
0.200) (Supplementary Fig. 2c, d).
We next asked whether gut microbiota depletion affected
UCP1-independent thermogenic mechanisms. We assessed
energy expenditure in ABX-treated Ucp1-KO mice after a 10 days
step-down cooling protocol (Fig. 2i, also see Methods for details).
Microbiota depletion did not affect body weight (two-way
ANOVA, F3, 31= 0.6147, P= 0.611) in Ucp1-KO mice after
3–4 weeks of ABX treatment (Supplementary Fig. 2e). Cold
adapted Ucp1-KO mice had elevated food intake compared to
mice at 22 °C (2-way ANOVA, F3, 31= 10.46, P < 0.001)
(Supplementary Fig. 2f). At 22 °C, ABX-treated Ucp1-KO mice
displayed comparable levels of total body fat and lean mass (two-
way ANOVA, F3, 62= 2.689, P > 0.999) (Fig. 2j and Supplemen-
tary Fig. 2g–k). Although the acute cold exposure stimulates
lipolysis, 10 days cold habituation increased the total fat mass
compared to that at room temperature. At 22 °C, ABX-treated
Ucp1-KO mice did not have significantly altered daily energy
expenditure (two-way ANOVA, F1, 13= 0.6596, P= 0.431)
(Fig. 2k). To measure the energy metabolism of cold habituated
mice at 4 °C, we used the doubly labeled water (DLW)
technique37. Compared to 22 °C, cold exposure elevated energy
expenditure in both Control and ABX-treated Ucp1-KO mice,
which reflected the activation of UCP1-independent thermogen-
esis. Importantly, ABX-treated Ucp1-KO mice did not differ in
their daily energy expenditure from Control Ucp1-KO mice at 4 °
C (one-way ANOVA, F3, 29= 0.5414, P > 0.999) indicating
microbiota depletion had minimal impact on UCP1-
independent adaptive thermogenesis (Fig. 2l). We repeated these
analyses using the approach suggested by Krisko et al.23
employing our previous dissection data to estimate the weight
of the cecum contents. We then subtracted these weights from the
total live mass before running the analysis. In the animals at room
temperature, we found no effect of the adjusted body weight
(ANCOVA, F1,12= 1.09, P= 0.318) and no effect of ABX
treatment (ANCOVA, F1,12= 0.43, P= 0.526). In the cold
exposed groups, we found a significant effect of the adjusted
weight (ANCOVA: F1,12= 6.83, P= 0.02) but no ABX treatment
effect (ANCOVA, F1,12= 1.54, P = 0.234). In other words, using
the analysis approach advocated by Krisko et al. (2020) made no
difference to the outcome that ABX treatment had no impact on
energy expenditure when UCP1 was absent.
UCP1 is dispensable for gut microbiota depletion-induced
glucose improvement. Numerous studies have suggested that
elevated UCP1 levels in BAT have a positive correlation with
raised metabolic rate and better glucose metabolism in both
rodents and humans38. Previous studies have linked the beneficial
effect of glucose metabolism in ABX mice to the elevated Ucp1
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mRNA expression and browning of inguinal and epididymal
WAT22. Contradicting these observations, we found that both
mRNA and protein levels of UCP1 in BAT and inguinal WAT
were decreased, whereas the expression of Ucp1 mRNA was
unchanged in cold stimulated ABX mice26. In this study, we also
observed glucose uptake to all depots of white adipose tissue was
unchanged in ABX mice, at room temperature and in cold con-
dition (Fig. 1d). To further evaluate whether UCP1 is essential for
the beneficial effect of gut microbiota depletion on glucose
clearance in obese mice, we administered ABX to 60% kcal high-
fat diet (HFD) (D12492, Research Diets, New Brunswick, NJ) fed
Ucp1-KO mice and their wild-type siblings for 4–5 weeks
Fig. 2 Gut microbiota is not required for UCP1-independent thermogenesis. a Experimental scheme. 16-weeks low fat diet (LFD)-fed Ucp1-KO mice and
its sibling controls subject to ABX treatment. Ucp1+: Ctrl group (black square) and Ucp1KO: Ctrl group (blue empty square) were control groups, Ucp1+:
ABX group (red circle) and Ucp1KO: ABX group (purple empty circle) received 4–5 weeks of ABX treatment (Ucp1+: Ctrl, n= 7; Ucp1+: ABX, n= 8; Ucp1KO:
Ctrl, n= 10; Ucp1KO: ABX, n= 12). The results shown are representative of two independent experiments. b Body composition at fourth week of ABX
treatment (Ucp1+: Ctrl, n= 7; Ucp1+: ABX, n= 8; Ucp1KO: Ctrl, n= 10; Ucp1KO: ABX, n= 11) (both P < 0.001). c, d Intraperitoneal glucose tolerance test
(ipGTT) and total glucose area under the curves (AUC) at the third week of ABX treatment (Ucp1+: Ctrl, n= 7; Ucp1+: ABX, n= 8; Ucp1KO: Ctrl, n= 10;
Ucp1KO: ABX, n= 12) (d: Ucp1+: Ctrl vs Ucp1+: ABX, P= 0.009; Ucp1+: Ctrl vs Ucp1KO: Ctrl, P= 0.003; Ucp1KO: Ctrl vs Ucp1KO: ABX, P < 0.001). e–h The
curve of oxygen consumption (e) and respiratory exchange ratio (g) after CL-316246 injection, and the average of oxygen consumption (f) and respiratory
exchange ratio (P= 0.033) (h) (Ucp1+: Ctrl, n= 7; Ucp1+: ABX, n= 8; Ucp1KO: Ctrl, n= 8; Ucp1KO: ABX, n= 9) (Ucp1+, P < 0.001; Ucp1KO, P= 0.002).
I Experimental scheme. LFD-fed Ucp1-KO mice subject to gradient cold stimulation and ABX treatment. Ucp1KO:Ctrl:22 °C (blue square) group was control;
Ucp1KO:Ctrl:4 °C (blue empty square) group habituated to 10 days of gradient cold stimulation; Ucp1KO:ABX:22 °C group (purple circle) group received
ABX treatment for 36 days; and Ucp1KO:ABX:4 °C (purple empty circle) group habituated to 10 days of gradient cold stimulation at 24th day of ABX
treatment until day 36 (Ucp1KO:Ctrl:22 °C, n= 8; Ucp1KO:Ctrl:4 °C, n= 9; Ucp1KO:ABX:22 °C, n= 8; Ucp1KO:ABX:4 °C, n= 10). J Final body composition
(Ucp1KO:Ctrl:22 °C, n= 8; Ucp1KO:Ctrl:4 °C, n= 9; Ucp1KO:ABX:22 °C, n= 8; Ucp1KO:ABX:4 °C, n= 10). k, l Daily energy expenditure at room temperature
(k) (Ucp1KO:Ctrl:22 °C, n= 8; Ucp1KO:Ctrl:4 °C, n= 9; Ucp1KO:ABX:22 °C, n= 7; Ucp1KO:ABX:4 °C, n= 9) or cold habituation (l) (Ucp1KO:Ctrl, n= 8;
Ucp1KO:ABX, n= 7;) in LFD-fed Ucp1-KO mice. All statistical analyses were performed by two-way ANOVA with Bonferroni’s multiple comparisons. All
results are given as mean ± SEM. Differences with P < 0.05 were considered to be significant. P < 0.05 (*), P < 0.01 (**), and P < 0.001 (***). See also
Supplementary Fig. 2.
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(Fig. 3a). Five weeks of ABX treatment at 22 °C did not affect
body weight (two-way ANOVA, F3, 29= 1.62, P= 0.206) or food
intake (two-way ANOVA, F3, 29= 2.161, P= 0.114) in HFD-fed
wild-type and Ucp1-KO mice (Fig. 3b and Supplementary
Fig. 3a). ABX treatment also did not affect total body fat mass in
HFD-fed Ucp1-KO mice (two-way ANOVA, F3, 57= 2.434, P=
0.336) or wild-type mice (two-way ANOVA, F3, 57= 2.434, P=
0.859) (Fig. 3c). There was no difference in tissue weight except
the enlarged intestine (two-way ANOVA, F3, 68= 11.48, P <
0.001) and cecum (two-way ANOVA, F3, 68= 11.48, P < 0.001)
after ABX treatment (Supplementary Fig. 3b–e). In the control
condition at 22 °C, consistent with previous studies33, HFD-fed
wild-type and Ucp1-KO mice had comparable daily energy
expenditure (ANCOVA, F3, 28= 1.126, P= 0.37). Microbiota
depletion also did not alter daily energy expenditure in wild-type
and Ucp1-KO mice (one-way ANOVA, F3, 29= 1.126, P= 0.475)
(Fig. 3d). To better understand the effect of microbiota depletion
on glucose metabolism, baseline ipGTT was performed 1 week
before ABX treatment and a second ipGTT was conducted on the
fourth week of ABX treatment. In the baseline state, although
Fig. 3 UCP1 is dispensable for gut microbiota depletion-induced glucose improvement. a Experimental scheme. 10-weeks high-fat diet (HFD)-fed Ucp1-
KO mice and its sibling controls subject to ABX treatment. Ucp1+:Ctrl group (black square) and Ucp1KO:Ctrl group (blue empty square) were Control
groups, Ucp1+:ABX group (red circle) and Ucp1KO:ABX group (purple empty circle) received 5 weeks of ABX treatment (Ucp1+: Ctrl, n= 9; Ucp1+: ABX,
n= 9; Ucp1KO: Ctrl, n= 7; Ucp1KO: ABX, n= 9). The results shown are representative of two independent experiments. b–d Body mass curves (b), final
body composition (c), and daily energy expenditure (d) of HFD-fed Ucp1-KO mice and its sibling at Control or ABX condition (Ucp1+: Ctrl, n= 8; Ucp1+:
ABX, n= 9; Ucp1KO: Ctrl, n= 7; Ucp1KO: ABX, n= 9). e, f Intraperitoneal glucose tolerance test (ipGTT) and total glucose area under the curves (AUC) at
the fourth week of ABX treatment (Ucp1+: Ctrl, n= 9; Ucp1+: ABX, n= 9; Ucp1KO: Ctrl, n= 7; Ucp1KO: ABX, n= 9) (Ucp1+, P= 0.011; Ucp1KO, P= 0.017).
g–i 2DG enrichment in fat depots (g), skeletal muscle (i), and other tissues (h) after intraperitoneal injection of [U-13C] labelled 2DG to mice at the 5th
week of ABX (Ucp1+: Ctrl, n= 8; Ucp1+: ABX, n= 9; Ucp1KO: Ctrl, n= 7; Ucp1KO: ABX, n= 7) (BAT, Ucp1+: Ctrl vs Ucp1+: ABX, P < 0.001; Ucp1+: ABX vs
Ucp1KO: ABX, P= 0.008; Ucp1KO: Ctrl vs Ucp1KO: ABX, P= 0.012). All statistical analyses were performed by two-way ANOVA with Bonferroni’s multiple
comparisons. All results are given as mean ± SEM. Differences with P < 0.05 were considered to be significant. P < 0.05 (*), P < 0.01 (**), and P < 0.001
(***). See also Supplementary Fig. 3.
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there was no difference in body weight or body fat, HFD-fed
Ucp1-KO mice had slower glucose clearance performance com-
pare to wild-type mice (two-way ANOVA, F1, 29= 6.15, P=
0.019) (Supplementary Fig. 3f, g). After ABX treatment, both
HFD-fed wild-type (two-way ANOVA, F12, 120= 2.951, P <
0.036) and Ucp1-KO mice (two-way ANOVA, F12, 120= 2.951, P
< 0.017) had significantly accelerated glucose clearance at 60 min
and 120 min (Fig. 3e) and their total glucose area under the curve
(AUC) was significantly lowered after ABX treatment (one-way
ANOVA, F3, 30= 4.831, P= 0.016) (Fig. 3f).
To determine the impact of ABX on glucose uptake in obese
Ucp1-KO mice, a 13C-labeled 2DG solution was used. Similar to
LFD-fed mice in Supplementary Fig. 1i, ABX treatment increased
13C levels in the cecum of both Ucp1-KO mice and wild-type
controls (two-way ANOVA, F3,29= 56.54, P= 0.01) (Supplemen-
tary Fig. 3h). ABX treatment also significantly elevated 13C 2DG
uptake to BAT in obese wild-type (two-way ANOVA, F3, 26=
4.00, P < 0.001) and Ucp1-KO (two-way ANOVA, F3, 26= 4.00, P
= 0.012) groups (Fig. 3g). Notably, the obese Ucp1-KO group had
significant lower 13C 2DG contents in BAT compared to wild-
type group when microbiota was depleted. 2DG contents in all
white adipose depots and remaining tissues including liver had no
changes (Fig. 3g–i and Supplementary Fig. 3i). Together, our data
indicated that at room temperature microbiota depletion
improved glucose clearance in both lean and obese mice, and
ABX treatment increased the glucose uptake in BAT and cecum.
This action was independent of total body weight, daily food
intake or the expression of UCP1.
Brown and beige adipocytes are indispensable for gut micro-
biota depletion-induced glucose improvement. In the glucose
tracer experiments, we found glucose uptake to both the BAT
(Figs. 1e and 3g) and cecum (Supplementary Figs. 1f and 3h) was
significantly increased. It has been documented that the capacity
to utilize glucose in BAT is positively associated with improve-
ment of glucose tolerance in both rodents and humans15,39. A
recent study found the cecum shifted energy utilization from
short-chain fatty acids to glucose when the microbiota was
absent20. To probe whether cells expressing UCP1 (Ucp1+) are
necessary for the glucose amelioration in ABX treatment, we
selectively deleted Ucp1+ cells in LFD-fed Ucp1DTR mice by
injection of diphtheria toxin (DT) during ABX treatment at 22 °C.
Ucp1DTR mice have a diphtheria toxin receptor (DTR) and an
EGFP cassette under the control of the Ucp1 promoter40, which
provides an inducible way to delete Ucp1+ cells without any
developmental deficit41,42. LFD-fed Ucp1DTR mice were ran-
domly divided into four groups: (1) Saline-Ctrl group, which
received subcutaneous saline injections and drank autoclaved
distilled water; (2) DT-Ctrl group, which were given sub-
cutaneous DT injections and drank autoclaved distilled water; (3)
Saline-ABX group, which received saline injections and were
administrated ABX in the autoclaved distilled water; and (4) DT-
ABX group, which were given subcutaneous DT injections and
ABX treatment (Fig. 4a and Supplementary Fig. 4a). Neither
depletion of microbiota nor deletion of Ucp1+ cells had an
impact on body weight in the Ucp1DTR mice (two-way ANOVA,
F3, 19= 1.860, P= 0.171) (Fig. 4b). DT injection significantly
lowered the BAT weight in DT-Ctrl and DT-ABX groups (one-
way ANOVA, F3, 19= 1.546, P < 0.001) (Supplementary
Fig. 4d–g). After 3 weeks of ABX and DT experiment, the Saline-
ABX treatment group showed an improvement compared to the
Saline-Ctrl group in ipGTT (two-way ANOVA, F3, 19= 8.91, P <
0.001). Noteworthy, the combination of DT and ABX treatment
neutralized the beneficial effect of ABX in ipGTT (Fig. 4c, d),
showing Ucp1+ cells are required for the ABX-mediated
improvement in the ipGTT. Both ABX treatment groups (Sal-
ine-ABX and DT-ABX) had a reduction of the oxygen con-
sumption during the night (two-way ANOVA, F3, 19= 4.208, P
= 0.015). We did not observe any difference in RER (Fig. 4g, h)
and physical activity among the four groups (Supplementary
Fig. 4b, c).
To further investigate whether Ucp1+ cells are essential for the
ABX-mediated glucose clearance in obese mice. We fed Ucp1DTR
mice with 60% kcal high-fat diet for 9–10 weeks (Fig. 5a),
following five weeks of ABX treatment at 22 °C. In the obese
Ucp1DTR mice, neither depletion of microbiota nor deletion of
Ucp1+ cells had an impact on body weight (two-way ANOVA,
F3, 22= 0.7478, P= 0.535) (Fig. 5b), daily food intake (two-way
ANOVA, F3, 22= 1.061, P= 0.386) (Supplementary Fig. 5a), or
body composition (two-way ANOVA, F3, 50= 4.598, P= 0.386)
(Fig. 5c) after 4 weeks treatment. Consistent with ABX-treated
obese Ucp1-KO mice, the intestine (two-way ANOVA, F3, 96=
212, P < 0.001) and cecum (two-way ANOVA, F3, 96= 212, P=
0.047) were heavier after ABX treatment and the weights of other
tissues remained unchanged (Supplementary Fig. 5b–e). A recent
study suggested Ucp1+ cells do not contribute to energy
expenditure at HFD-fed state42. Confirming this finding, we also
found that Ucp1+ cells had no impact on energy expenditure
when the microbiota was depleted (ANCOVA, F3, 15= 0.5, P=
0.69) (Fig. 5d). Before the ABX treatment was started, baseline
ipGTT (two-way ANOVA, F3, 28= 0.11, P= 0.953) and AUC
(one-way ANOVA, F3, 28= 0.26, P= 0.26) were not significantly
different between the four groups (Supplementary Fig. 5f, g).
After 4 weeks of ABX and DT experiment, compared to the
Saline-Ctrl group, the DT-Ctrl group (two-way ANOVA, F3, 28=
6.12, P= 0.048) had deteriorated ipGTT performance, whereas
the Saline-ABX treatment group showed an improvement (two-
way ANOVA, F3, 28= 6.12, P= 0.037). Noteworthy, the combi-
nation of DT and ABX treatment neutralized the beneficial effect
of ABX on ipGTT (Fig. 5e, f), showing Ucp1+ cells are necessary
for the ABX-mediated improvement on ipGTT.
To determine the influence of depletion of Ucp1+ cells on the
uptake of glucose across tissues when the microbiota was
deficient, we injected 13C-labeled 2DG solution at the 5th week
of the experiment. Consistent with the 13C 2DG result in ABX-
treated obese wild-type mice at Supplementary Fig. 3h, the Saline-
ABX group (two-way ANOVA, F3, 24= 6.82, P < 0.001) and DT-
ABX group (two-way ANOVA, F3, 24= 6.82, P < 0.001) both had
increased 13C 2DG contents in cecum compared to the two non-
ABX-treated groups (Supplementary Fig. 5h). Similar to the result
in Fig. 3g, the Saline-ABX group had enhanced 2DG levels in
BAT compared to the Saline-Ctrl group (two-way ANOVA, F3, 89
= 18.12, P= 0.027) and unchanged 2DG levels in both WAT and
liver (Fig. 5g). Both the DT-Ctrl group and DT-ABX group (two-
way ANOVA, F3, 89= 18.12, P < 0.001) had significantly impaired
13C 2DG uptake in BAT, demonstrating that depletion of Ucp1+
cells impaired glucose uptake to BAT (Fig. 5g). 2DG contents in
heart also decreased following DT injection (two-way ANOVA,
F3, 90= 1.513, P < 0.001). DT injection did not affect 13C 2DG
contents in all the white adipose depots (two-way ANOVA, F3, 69
= 0.4416, P= 0.724) suggesting that the depletion of Ucp1+ beige
adipocytes had no effect to 2DG uptake in ABX-treated mice
(Fig. 5g). The remaining tissues including liver (two-way
ANOVA, F3, 24= 0.1213, P= 0.947) and muscle had no
difference in 2DG uptakes (Fig. 5h, i and Supplementary Fig. 5i).
These data indicated that BAT, rather than liver or WAT depots
(e.g., inguinal or epididymal WAT), is the key organ in
modulating glucose clearance when the gut microbiota was
depleted.
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Discussion
Increasing numbers of studies have established a connection
between the gut microbiota and host metabolism in both mice
and humans29,43–45. Although one recent study suggested
microbiome-deficient mice exhibited no differences in tolerance
to glucose23, many previous studies have found that microbiota
depletion, using either antibiotic treatment or GF models,
improves glucose tolerance19,20,22,46. Our first experiment was to
reconfirm whether microbiota deficiency causes improvement in
the ipGTT in wild-type mice. We found that microbiota depletion
accelerated glucose clearance from circulation, and ABX mice had
higher 13C CO2 peak output at 4 °C after 13C glucose injection
indicating the mice preferred to metabolize the injected energy
substrate when the microbiota was absent. Our isotope tracing
experiments evaluated 13C-labeled glucose and 2DG contents in
22 tissues in Control mice and this indicated that cold exposure
only stimulated uptake of glucose in BAT. This reflects the well-
established physiological acclimation response, whereby rodents
shift the source of heat production from shivering in skeletal
muscles to nonshivering thermogenesis (NST) in BAT after 48 h
cold stimulation47. It is noteworthy that the glucose uptake in
skeletal muscle was not decreased in ABX mice after acute cold
exposure indicating a possible extension of shivering in ABX
mice48. A previous study linked improvement in glucose meta-
bolism in ABX mice to elevation of glucose uptake in inguinal
WAT22, although uptake to other tissues was not studied. Here,
we found that BAT had greatly enhanced glucose uptake while all
the WAT depots had negligible changes when the microbiota was
absent (Fig. 1e, h). Since it was already characterized22,23,26 that
the microbiota-deficient mice have lower body fat mass compare
to Control mice under LFD conditions (Supplementary Fig. 1d),
the total contribution of WAT depots to glucose uptake is even
lower in ABX-treated mice.
Importantly, ABX mice not only had higher glucose uptake in
BAT, but also showed elevated glucose uptake in the digestive
organs, suggesting these tissues are important for glucose uptake.
Depletion of Ucp1+ cells fully blocked the beneficial effect of
ABX in ipGTT indicating that BAT is required for the improved
glucose clearance when the gut microbiota was absent. We did
not determine whether the cecum is also necessary for this action
in this study. Although a recent study addressed ABX treatment
mice with the cecum removed, cecum removal only partially
blunted the effect of ABX on glucose clearance23. The liver is an
important organ for the glycogen synthesis. In current study, we
mainly focused on glucose uptake and glucose clearance. It
remains to be studied whether microbiota depletion also affects
Fig. 4 Deletion of Ucp1+ cells in lean mice blocked the gut microbiota depletion-modulated glucose clearance improvement. a Experimental scheme.
10-weeks low fat diet (LFD)-fed Ucp1DTR mice were divided into four groups. Saline-Ctrl group (black square) received subcutaneous saline injections and
drank autoclaved water; DT-Ctrl group (orange square) given subcutaneous DT injection and drank autoclaved water; Saline-ABX group (red circle)
received saline injections and ABX treatment; and DT-ABX group (orange open circle) given subcutaneous DT injection and ABX treatment (Ucp1DTR:
Saline:Ctrl, n= 6, Ucp1DTR:DT:Ctrl, n= 6; Ucp1DTR:Saline:ABX, n= 6; Ucp1DTR:DT:ABX, n= 6). The results shown are representative of two independent
experiments. b Body mass curves of four different treated HFD-fed Ucp1-DTR mice (Ucp1DTR:Saline:Ctrl, n= 6, Ucp1DTR:DT:Ctrl, n= 6; Ucp1DTR:Saline:
ABX, n= 6; Ucp1DTR:DT:ABX, n= 5). The results shown are representative of two independent experiments. c, d Intraperitoneal glucose tolerance test
(ipGTT) and total glucose area under the curves (AUC) at the third week of treatment (Ucp1DTR:Saline:Ctrl, n= 6, Ucp1DTR:DT:Ctrl, n= 6; Ucp1DTR:Saline:
ABX, n= 6; Ucp1DTR:DT:ABX, n= 5) (c: Ucp1DTR:Saline:Ctrl vs Ucp1DTR:Saline:ABX, P < 0.001 at T= 30min, P= 0.016 at T= 60min; d: Saline:Ctrl vs
Saline:ABX, P= 0.017, Saline:ABX vs DT:ABX, P= 0.001). e–h The curve of oxygen consumption (e) and respiratory exchange ratio (g) in 24 h, and the
average of oxygen consumption (f) and respiratory exchange ratio (Ucp1DTR:Saline:Ctrl vs Ucp1DTR:Saline:ABX, P= 0.011; Ucp1DTR:DT:Ctrl vs Ucp1DTR:DT:
ABX, P < 0.018) (h) in day and night states (Ucp1DTR:Saline:Ctrl, n= 6, Ucp1DTR:DT:Ctrl, n= 6; Ucp1DTR:Saline:ABX, n= 6; Ucp1DTR:DT:ABX, n= 5). DT
diphtheria toxin, DTR diphtheria toxin receptor. All statistical analyses were performed by two-way ANOVA with Bonferroni’s multiple comparisons. All
results are given as mean ± SEM. Differences with P < 0.05 were considered to be significant. P < 0.05 (*), P < 0.01 (**), and P < 0.001 (***). See also
Supplementary Fig. 4.
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hepatic gluconeogenesis, since the hepatic glycogen in the pyr-
uvate tolerance test could be fast uptake by BAT and cecum from
the circulation in ABX mice.
A recent study proposed that the gut microbiota does not
impact adaptive thermogenesis23 but rather the observed effect is
due to an artefact stemming from enlargement of the cecum in
ABX-treated individuals. To account for this effect, they evaluated
energy expenditure in mice with the cecum removed, or they
adjusted total body mass for the intestinal contents measured
post-mortem. However, there are several issues with these
approaches. In particular cecectomy, enterocyte populations that
may be involved in the regulation of energy balance through
communicating with other gut tissues, and production of gut
hormones such as secretin49, glucagon-like peptide 1 (GLP-1)50.
Moreover, ABX mice and GF mice have impaired absorption
efficiency due to the lack of gut microbiota. The extended
intestine and enlarged cecum are the physiological compensation
to sustain energy assimilation in the microbiota-depleted mice.
Therefore, the surgical removal of the cecum might affect the
metabolic activity of other tissues and eventually impact on the
whole-body energy expenditure. At last, the cecum is also known
to be highly metabolically activated when the gut microbiota is
depleted20. A recent study reported that antibiotic induced
microbiota depletion alters gut signaling and cecum metabolism.
Fig. 5 Ucp1+ cells are indispensable for gut microbiota depletion-induced glucose improvement in obese mice. a Experimental scheme. 10-weeks HFD-
fed Ucp1DTR mice were divided into four groups. Saline-Ctrl group (black square) received subcutaneous saline injections and drank autoclaved water; DT-
Ctrl group (orange square) gave subcutaneous DT injection and drank autoclaved water; Saline-ABX group (red circle) received saline injections and ABX
treatment; and DT-ABX group (orange open circle) gave subcutaneous DT injection and ABX treatment. The results shown are representative of two
independent experiments. b–d Body mass curves (b), final body composition (c), and daily energy expenditure (d) of four different treated HFD-fed Ucp1-
DTR mice (b, c: Ucp1DTR:Saline:Ctrl, n= 7, Ucp1DTR:DT:Ctrl, n= 6; Ucp1DTR:Saline:ABX, n= 9; Ucp1DTR:DT:ABX, n= 9; d: Ucp1DTR:Saline:Ctrl, n= 3,
Ucp1DTR:DT:Ctrl, n= 4; Ucp1DTR:Saline:ABX, n= 6; Ucp1DTR:DT:ABX, n= 7;). e, f Intraperitoneal glucose tolerance test (ipGTT) and total glucose area
under the curves (AUC) at the 4th week of treatment (Ucp1DTR:Saline:Ctrl, n= 7, Ucp1DTR:DT:Ctrl, n= 6; Ucp1DTR:Saline:ABX, n= 10; Ucp1DTR:DT:ABX,
n= 10) (e: P= 0.037 at T= 30min, P= 0.045 at T= 60min; f: Ctrl, P= 0.012; DT, P= 0.012; Saline, P= 0.026;). g–i 2DG enrichment in fat depots (g),
skeletal muscle (I), and other tissues (h) after intraperitoneal injection of [U-13C] labelled 2DG to mice at the 5th week of treatment (Ucp1DTR:Saline:Ctrl,
n= 7, Ucp1DTR:DT:Ctrl, n= 6; Ucp1DTR:Saline:ABX, n= 8; Ucp1DTR:DT:ABX, n= 7) (BAT:Ctrl, P < 0.001; ABX, P < 0.001; Saline, P= 0.027; Heart:Ctrl, P=
0.007;). DT diphtheria toxin, DTR diphtheria toxin receptor. All statistical analyses were performed by two-way ANOVA with Bonferroni’s multiple
comparisons. All results are given as mean ± SEM. Differences with P < 0.05 were considered to be significant. See also Supplementary Fig. 5. P < 0.05 (*),
P < 0.01 (**), and P < 0.001 (***).
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They found that gut microbiota depletion promoted a shift of
substrate utilization from SCFA to glucose. Consistent with their
finding, we also found the cecum of ABX mice imported higher
glucose contents than Control mice in both lean and obese state
(Fig. 1j and Supplementary Figs. 1i, 3h, 4h).
Adjusting the body mass used in analysis of covariance51 to
account for the cecum contents may be a way around these issues
with cecectomy23. When we used this approach in the current
data, we found that the ‘Krisko adjustment’ had no impact on the
outcome of the analysis (ANCOVA, F1,12= 0.43, P= 0.526). We
previously found that ABX mice had lower total energy expen-
diture after adjusted with body mass or lean mass using
ANCOVA26. To evaluate the impact of adjusting the body mass
estimates using the ‘Krisko adjustment’ in this previous experi-
ment, we calculated the adjusted body masses using post-mortem
estimates of cecum contents derived from a separate cohort. The
previous analysis indicated that there was no significant impact
body mass (ANCOVA, F1,23= 0.49, P = 0.49) but a significant
impact of the ABX treatment (ANCOVA, treatment F1,23=
6.69, P= 0.016). After adjustment of the body masses we also
found no effect of mass and the ABX treatment effect became
(ANCOVA, F1,23= 4.19, P= 0.052). Technically this is not sta-
tistically significant. However, there are several caveats worth
noting before we consider discarding the previous result. First, we
used the masses of the cecum contents from a separate cohort
hence the applicability of these values to the mice we measured is
uncertain. Specifically, we may have overcorrected for the mass of
the caecum contents. Second, there is a strong movement away
from rigorous application of P-value thresholds to establish sta-
tistical inference52–54. A P-value of 0.052 indicates that the value
0 lies just inside the confidence interval of the estimated effect
size. Hence, it also means that while these data do not allow us to
reject the hypothesis that the effect is 0, they also do not allow us
to reject the hypothesis that the effect size is on the upper side of
the confidence limit—in this case an effect on the metabolic rate
of 14%. If we took a Bayesian approach to the analysis and spe-
cified a prior that we expected an effect of ABX on metabolism of
10%, then we would be unable to reject that hypothesis with
either the unadjusted or ‘Krisko adjusted’ data. Finally, since in
this experiment there was no significant effect of body mass, it is
questionable whether it is actually necessary to include body mass
into the ANCOVA model, and if removed the ABX treatment
effect becomes highly significant (F1,24= 18.6, P < .001). We
suggest based on these analyses of our previous data, combined
with the data presented here that the most parsimonious inter-
pretation is that ABX treatment causes a reduction in metabolic
rate, but that this impact disappears when UCP1 is absent.
In our previous study, we found the gut microbiota depletion
impaired the Ucp1-dependent thermogenesis by blunting UCP1
expression during acute cold stimulation26,55. But UCP1 medi-
ated thermogenesis is not the only mechanism for elevating heat
production7,8, therefore we aimed to evaluate the impact of gut
microbiota on UCP1-independent thermogenesis. Acute and
chronic (the step-down cooling protocol) cold exposure will
activate both Ucp1-dependent and Ucp1-independent
thermogenesis4,5. We confirmed that ABX treatment impaired
the β3-adrenoceptor agonist induced (i.e., UCP1-dependent)
adaptive thermogenesis in wild-type mice. Next, we found that
microbiota depletion had a negligible impact on UCP1-
independent adaptive thermogenesis using Ucp1-KO mice. It is
still unclear why the UCP1-independent thermogenic pathway
remains intact where UCP1-dependent pathway was dampened
in gut microbiota-deficient mice. One possibility is that gut
microbiota-derived metabolites were not required for UCP1-
independent thermogenesis.
Our data have potential translational implications for treating
diabetes. In the last decades, it has been confirmed that adult
humans possess BAT depots and the size and activity of BAT is
related to ambient temperature and the state of adiposity12,56,57.
Similar to cold induced thermogenesis, early observations in the
1970s suggested that BAT is involved in diet-induced thermo-
genesis (DIT) in humans58 and this prandial thermogenesis has
recently been linked to the gut hormone Secretin and plays an
important role in regulating satiety49,59. Several studies have
proposed that physiological or pharmacological activation of BAT
thermogenesis leads to elevated energy expenditure, associated
with improved glucose metabolism in both rodents and
humans15,56,60. While it is initially surprising in our study that
the beneficial effect of microbiota depletion in glucose metabo-
lism was regulated by BAT, independent of adaptive thermo-
genesis, there is no a priori reason to assume that the contribution
of BAT to the improvement of glucose metabolism should be
dependent on activated thermogenesis. Current research efforts
have focused on how to activate BAT thermogenesis or recruit
more beige/brite adipocytes to improve blood glucose, but some
pharmacological agents which increase UCP1 content have side
effects such as elevated blood pressure which potentially increases
cardiovascular risk61. We found that the glucose control function
in BAT can be dissociated from the adaptive thermogenesis and
UCP1. In this case, our study potentially opens a new avenue for
study of the relationship between thermogenesis and glucose
metabolism in BAT. Future studies will focus on the glucose
regulation mechanism underpinning the gut-BAT axis.
Our study has several limitations that we acknowledge here.
First, although we complied over 2700 measurements of 13C
contents in 22 different tissues using two glucose tracers, we were
only able to address that BAT is essential for the gut microbiota
mediated glucose improvement. 13C glucose metabolic flux was
not determined in mice and it is important to understand how
BAT utilizes the imported glucose under normal and microbiota-
deficient state. It is also possible that a small subset, not all, of
brown adipocytes modulated the glucose uptake in ABX mice62.
Moreover, we only analyzed glucose contents at one-timepoint,
which was the relative peak point of CO2 output. It is possible
that other tissues are important for uptake and utilization at
different time points. Second, it has been documented that, in
addition to classic interscapular BAT, more BAT-like and brite/
beige adipose depots have been confirmed in mice using an
image-guide approach63. Using Ucp1-DTR mice, we are able to
delete Ucp1+ cells in BAT and these BAT-like depots. It is cur-
rently unclear what the ability for glucose uptake is in these BAT-
like depots, and is possible that other BAT-like depots also
enhanced their glucose uptake capacity when the microbiota was
absent. Third, we used 13C-labeled 2DG as indicator to measure
the cumulative glucose uptake. It is important to point out that
2DG disrupts the glucose sensor system and leads to
hyperglycemia64. It is possible that 2DG contents do not reflect
the actual glucose distribution, even though we obtained a similar
readout with the 13C glucose tracer. Hence, to avoid the impact of
2DG on the glucose metabolism, we perform ipGTT first in HFD-
fed Ucp1-KO and Ucp1-DTR mice, then 1 week later mice were
injected with 13C 2DG tracer, which was mixed with glucose
solution. Lastly, all the experiments were performed in C57BL/6
N mice background including Ucp1-KO mice which was ori-
ginally generated in a mixture of C57 and Sv129 background.
Different mouse strains in different house conditions, age, cold
exposure programs, antibiotic administration route (drinking
water or gavage), diets (LFD or chow), and other factors65 might
have different background in gut microbiota composition leading
to different readouts in glucose tolerance tests and energy
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expenditure assays. Despite these limitations, our study still
explains the role of BAT in gut microbiota depletion mediated
glucose improvement and offers some important insights into
future studies using ABX mouse models to further investigate the
glucose homeostasis mechanisms underpinning the gut-BAT axis.
In summary, our data highlight the important role for gut-BAT
axis in regulating glucose metabolism. We confirmed that
antibiotic-mediated microbiota depletion improves glucose tol-
erance in mice. Using isotope labeled glucose tracers, we found
that microbiota depletion significantly enhanced the ability of
glucose uptake in BAT, rather than in the WAT or liver.
Microbiota depletion does not negatively affect UCP1-
independent thermogenic mechanisms, unlike the impact on
UCP1-dependent processes. Furthermore, this improvement of
glucose metabolism in ABX mice does not require UCP1 but can
be blocked through selective deletion of brown adipocytes. This
suggests substantive UCP1-independent glucose utilization
in BAT.
Methods
Experimental models. All animal procedures were approved by the Institute of
Genetics and Developmental Biology Chinese Academy of Sciences (IGDB-CAS)
Institutional Animal Care and Use Committee (IACUC). All relevant ethical reg-
ulations have been complied. All mouse experiments were performed in male mice
and all mice were housed in specific-pathogen-free facility (SPF) kept at 23 ± 1 °C
and 50% humidity with a dark-light cycle of 12 h:12 h (lights on at 07:30) and fed
ad libitum with a standard chow diet (20% kcal Protein, 70% kcal Carbohydrate
and 10% kcal Fat, #D12450B, Research Diets, New Brunswick, NJ) in all LFD
experiments or with a high-fat diet (20% kcal Protein, 20% kcal Carbohydrate, and
60% kcal Fat, #D12492, Research Diets, New Brunswick, NJ) in all HFD experi-
ments. Mice were provided with autoclaved drinking water. Antibiotics were
administered in the sterile drinking water ad libitum and changed every 3 days,
ABX protocol containing ampicillin (0.5 mg/mL, J&K, Cat# A01-290395), neo-
mycin (0.5 mg/mL, J&K, Cat# A01-557926), gentamicin (0.5 mg/mL, J&K, Cat#
A01-405947), metronidazole (0.5 mg/mL, J&K, Cat# J07-M0924), vancomycin
(0.25 mg/mL, INALCO, Cat# 1758-9326), and sucralose (4 mg/mL, Splenda, J&K,
Cat# A01-442522)30. In LFD experiments, antibiotics treatment started at 8–9-
weeks-old mice for about 4–5 weeks. In HFD experiments, antibiotics treatment
started at 19-week-old obese mice. For acute cold challenge experiment, mice were
fed ad libitum and individually housed at 4 °C for 48 h. For the chronic cold
challenge experiment, mice were fed ad libitum and individually housed, ambient
temperature was decreased from 22 °C to 4 °C (−2 °C per day) which was con-
trolled by a laboratory incubator. In HFD experiments, mice were fed with high-fat
diet starting at 9 week old for 10 weeks, then were treated with ABX for about
4–5 weeks.
Metabolic phenotype analysis. We used magnetic-resonance whole-body com-
position analyzer to analyze mice body composition (fat mass, lean mass and water
content). The body weight and food intake were measured daily. We assessed
energy expenditure and physical activity by using indirect calorimetric system (TSE
PhenoMaster, TSE Systems, Bad Homburg, Germany). Daily energy expenditure
(DEE) of HFD-fed mice were measured by using the doubly labelled water (DLW,
2H218O) technique37,66. To assess the effect of b3-adrenergic agonist CL-316243 on
the energy expenditure, we treated mice daily for 3 consecutive days through
intraperitoneal administration of either vehicle (PBS) or CL-316243 (1 mg/kg,
Sigma, Cat# C5976).
Diphtheria toxin injection. To delete Ucp1+ cells, Ucp1-DTR mice were subjected
to two subcutaneously injection with 400 ng Diphtheria toxin (Sigma, Cat# D0564)
or PBS every 8 h at the scapular region for two continuous days. Two days after
injection, we repeated the injection route again depending the experimental design.
Glucose tolerance tests. Overnight fasting (16 h) mice were received an i.p.
injection of 20% glucose solution at dose of 2 g glucose per kg body weight (2 g/kg
BW). Blood glucose were taken from tail vein before injection and at 15, 30, 60, and
120 min after injection, then were determined by OneTouch glucometer.
13C enrichment in breath samples. We have developed a technique to measure
the glucose homeostasis by using [U13C]–glucose (Cambridge Isotope Lab, Cat#
CLM-1396-PK). The mice were fasted overnight before the experiment and
transferred to a small chamber with a constant gas flow after the i.p. injection of 2
g/kg BW [U13C]–glucose, which were diluted by [U12C]–glucose at a ratio of 1:19.
The flow is regulated such that the outflow CO2 is around 0.5%. This is 20 × higher
than the atmospheric CO2 hence incoming CO2 has only a negligible impact on the
measurements. The outflow stream is then sampled at 10-min intervals by col-
lecting gas into a standard vacutainer for up to 200 min. The air samples were
analyzed using an auto-sampler linked to a conventional gas source isotope ratio
mass spectrometer (Microgas uG). [U13C]–glucose in circulation enters cells and
then is metabolized and appears as 13CO2 in the breath. Hence by collecting breath
and measuring the 13C:12C ratio in respiratory CO2, the rate of glucose clearance
from the body was measured. This provides real time readout of the glucose in a
stress free and more detailed manner than the standard test provides.
13C enrichment in tissue samples. We developed a isotope-based method allowing
us to explore the tissue specific glucose uptake, based on the method used in optical
in vivo imaging of glucose metabolism67. Glucose uptake into cells can be measured
using 13C universal labelled 2-deoxy-D-glucose ([U-13C]–2DG) (Cambridge Isotope
Lab, Cat# CLM-10466). 2DG has the hydroxyl group on the second carbon molecule
replaced by a hydrogen. It has been known since the 1950s that this change does not
impair uptake into cells, via the glucose transporters, but the 2DG cannot be meta-
bolized by the process of glycolysis32. The mice were fasted overnight and received an
i.p. injection of 2 g/kg BW [U-13C]–2DG diluted with [U-12C]–glucose at a ratio of
1:9. After 25min, the mice were anesthetized by 0.1% isoflurane. Then the mice were
rapidly dissected within 5min for the collecting of fresh tissues following a perfusion
with sterile saline. The tissues were weighted and dried for 2 weeks in a 60 °C oven.
Then whole dry tissues were weighted and ground into powder, which can be ana-
lyzed by a mass spectrometer. By measuring the 13C:12C ratio in tissues dry weight,
the rate of glucose uptake into different tissues was measured. The [U-13C]–glucose
was used to measure dynamic glucose homeostasis in different tissues with the same
method. To estimate the tissue turnover we used an exponential uptake-elimination
model. That is we defined the glucose uptake from the 13C-2-dG levels, minus the
background isotope enrichment, and then calculated turnover from the difference
between the loge(13C-2-dGlucose) and loge(13C Glucose) at the 30min timepoint
(both expressed minus the background enrichment of 13C. The scaled C13 heatmaps
were generated in R version 4.03.
Western blotting. The whole adipose tissue pads were homogenized in tissue
protein extraction reagent (ThermoFisher, Cat# 78510) supplemented with a
protease inhibitor cocktail (Sigma, Cat# P8340) and 10 mM PMSF (Sigma, Cat#
P7626) and the lysates were chilled on ice for 30 min then centrifuged at 13,800 × g
(10 min) to remove cell debris. The supernatant was collected then the protein
concentration was measured by bicinchoninic acid (BCA) protein quantification
kit. Equal amounts of protein were separated on 12% SDS-PAGE gels and blotted
onto Immobilon-P PVDF membranes. After blocking in 5% skim milk in PBS-T
(PBS with 0.05% Tween-20) for 1 h at room temperature, membranes were incu-
bated with primary antibody at 4 °C overnight. To visualize the bands, HRP-labeled
secondary antibodies (Goat anti-Mouse IgG HRP antibody, Cat# ZB-2305, 1:5,000
diluted; Goat anti-Rabbit IgG HRP antibody, Cat#ZB-2301, 1:5,000 diluted) and
ECL blotting reagents (GE Healthcare) were used. The bands were quantified with
ImageJ 1.50i software. The primary antibodies used for western blot were UCP1
(Abcam, Cat# ab10983, 1:3,000 diluted), β-actin (ZSGB-Bio, Cat# TA-09, 1:5,000
diluted).
Quantification and statistical analysis. Replicate information is indicated in the
figure legends. All results are given as mean ± SEM and analyzed by using statistical
tools implemented in Prism (GraphPad version 8). Statistical analyses were per-
formed using the Student’s t-test and regular one-way or two-way analysis of
variance (ANOVA) with Bonferroni correction. Differences with P < 0.05 were
considered to be significant. P < 0.05 (*), P < 0.01 (**), and P < 0.001 (***).
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
All raw data generated or analyzed during this study are in this published articles and its
supplementary information files. Source data are provided with this paper.
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